Trials / Completed
CompletedNCT00329966
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older
A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Commercially Available Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2006-2007, When Administered to Non-Elderly Adult and Elderly Subjects
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
To evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged 18 years and over
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Surface Antigen, Inactivated, Influenza (form.2006-07) |
Timeline
- Start date
- 2006-06-01
- First posted
- 2006-05-25
- Last updated
- 2006-09-14
Locations
2 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00329966. Inclusion in this directory is not an endorsement.